1-3 of 3
Didier Decaudin, MD, PhD
Close
Sort by
Journal Articles

Imatinib Mesylate Reduces Rituximab-Induced Tumor Growth Inhibition In Vivo on EBV-Associated Human B-Cell Lymphoma.

Fariba Némati, PhD, Claire Mathiot, MD, Isabelle Grandjean, PhD, Olivier Lantz, MD, PhD, Vincent Bordier, Sébastien Dewulf, Richard Ekue, James P. Di Santo, PhD, Marie-France Poupon, MD, PhD, Didier Decaudin, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2360.
https://doi.org/10.1182/blood.V110.11.2360.2360
Published: 2007
Journal Articles

Radioimmunotherapy (RIT) of Refractory or Relapsed Hodgkin’s Lymphoma (HL) with 90 Yttrium-Labelled Antiferritin Antibody.

Didier Decaudin, MD, PhD, Rafaël Lévy, MD, François Lokiec, PD, PhD, Olivier Madar, PD, Rémi Brossel, MD, Franck Morschhauser, MD, Valentine Songeur, Malika Djeridane, Jean Kadouche, Alain Pecking, MD
Journal: Blood
Blood (2007) 110 (11): 4473.
https://doi.org/10.1182/blood.V110.11.4473.4473
Published: 2007
Journal Articles

A Multicenter Study of a Gemcitabine-Based Regimen in Relapsed or Refractory Hodgkin’s Lymphoma Patients.

Patricia Validire, MD, Christophe Fermé, MD, Pauline Brice, MD, Marine Diviné, MD, Jean Gabarre, MD, Krimo Bouabdallah, MD, Olivier Fitoussi, MD, Driss Chaoui, MD, Hélène Pacquement, MD, Carole Soussain, MD, Patrice Carde, MD, Rafika Sahli, MD, Didier Decaudin, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4436.
https://doi.org/10.1182/blood.V110.11.4436.4436
Published: 2007